跳至主要内容
临床试验/NCT04774315
NCT04774315进行中(未招募)4 期

Molecular Endotypes of Chronic Idiopathic Urticaria

University of Colorado, Denver1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2022年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
15
试验地点
1
主要终点
Responders

研究概览

简要总结

This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CIU as defined as frequent urticarial lesions for ≥ 6 weeks
  • Symptoms not controlled with standard dose antihistamines (loratadine 10mg daily, desloratadine 5mg daily, fexofenadine 180mg daily, cetirizine 10mg daily, or levocetirizine 5mg daily)
  • Planned initiation of treatment with omalizumab (Xolair) as part of standard of care for antihistamine-refractory urticaria

排除标准

  • Use of immunomodulatory drugs in the past 1 month prior to beginning the study
  • Use of systemic steroids in the past 1 month prior to beginning the study
  • Use of omalizumab in the past 3 months prior to beginning the study
  • Use of any investigational agent in the past 30 days
  • Untreated intercurrent illness
  • Severe Asthma
  • Primary diagnosis of flushing

研究组 & 干预措施

Omalizumab

Experimental

干预措施: Omalizumab (Drug)

结局指标

主要结局

Responders

时间窗: Week 16

The number of participants who meet the definition of "Responder" to omalizumab. "Responders" are defined as having a UAS7 of 6 or less after 16 weeks of treatment.

次要结局

  • Baseline expression of innate immune markers(Baseline)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验